Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/249125 http://scihub22266oqcxt.onion/10.1155/2015/249125 C4553342!4553342!26351570     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Ophthalmol 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=26351570|t=2015. Graves Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management |pdf=|usr=}}{{26351570}} gab.com Text Graves Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management JO: J Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=26351570 #FOAvip Graves' ophthalmopathy (GO) is an autoimmune inflammatory disorder associated with thyroid disease which affects ocular and orbital tissues. GO follows a biphasic course in which an initial active phase of progression is followed by a subsequent partial regression and a static inactive phase. Although the majority of GO patients have a mild, self-limiting, and nonprogressive ocular involvement, about 3?7% of GO patients exhibit a severe sight-threatening form of the disease due to corneal exposure or compressive optic neuropathy. An appropriate assessment of both severity and activity of the disease warrants an adequate treatment. The VISA (vision, inflammation, strabismus, and appearance), and the European Group of Graves' Orbitopathy (EUGOGO) classifications are the two widely used grading systems conceived to assess the activity and severity of GO and guide the therapeutic decision making. A critical analysis of classification, assessment, and management systems is reported. A simplified ?GO activity assessment checklist? for routine clinical practice is proposed. Current treatments are reviewed and management guidelines according to the severity and activity of the disease are provided. New treatment modalities such as specific monoclonal antibodies, TSH-R antagonists, and other immunomodulatory agents show a promising outcome for GO patients. Twit Text FOAVip Graves Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management ????J Ophthalmol http://www.kidney.de/pget.php?&tw=1&pmid=26351570 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26351570 #FOAvip English Wikipedia <ref>{{Cite pmid|26351570}}</ref> Graves Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management #MMPMID26351570 Barrio-Barrio J; Sabater AL; Bonet-Farriol E; Velázquez-Villoria Á; Galofré JC J Ophthalmol 2015[]; 2015 (ä): ä PMID26351570show ga Graves' ophthalmopathy (GO) is an autoimmune inflammatory disorder associated with thyroid disease which affects ocular and orbital tissues. GO follows a biphasic course in which an initial active phase of progression is followed by a subsequent partial regression and a static inactive phase. Although the majority of GO patients have a mild, self-limiting, and nonprogressive ocular involvement, about 3?7% of GO patients exhibit a severe sight-threatening form of the disease due to corneal exposure or compressive optic neuropathy. An appropriate assessment of both severity and activity of the disease warrants an adequate treatment. The VISA (vision, inflammation, strabismus, and appearance), and the European Group of Graves' Orbitopathy (EUGOGO) classifications are the two widely used grading systems conceived to assess the activity and severity of GO and guide the therapeutic decision making. A critical analysis of classification, assessment, and management systems is reported. A simplified ?GO activity assessment checklist? for routine clinical practice is proposed. Current treatments are reviewed and management guidelines according to the severity and activity of the disease are provided. New treatment modalities such as specific monoclonal antibodies, TSH-R antagonists, and other immunomodulatory agents show a promising outcome for GO patients. äGraves Ophthalmopathy: VISA versus EUGOGO Classification, Assessment,(epmc).pdf DeepDyve Pubget Overpricing